Bitcoin whale addresses now hold 3.03 million BTC, the highest since November 2025, indicating a shift from selling to accumulation by large holders. The 30-day growth rate of whale holdings is the fastest since February 2026. Meanwhile, US spot Bitcoin ETFs have recorded net inflows of about 2,300 BTC this year, reversing earlier outflows. Borrowing trends differ by size, with large borrowers increasing loans backed by Bitcoin, while smaller borrowers reduce theirs, highlighting growing confidence among major investors.
Bitcoin whale holdings reaching 3.03 million BTC provide context for Pluang's cryptocurrency market snapshot. For readers following major crypto assets, as of Oct 14, 2026 01:03 WIB, out of 50 major cryptocurrencies on Pluang, 13 rose and 36 fell. Kusama (KSM) and Zilliqa (ZIL) both declined by around 4.7%, with KSM at Rp83.560 and ZIL at Rp61, while Algorand (ALGO) dropped 4.43% to Rp2.137 but saw a majority buy order activity of 56%, contrasting with the heavy sell pressure on KSM and ZIL.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
